2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib

EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib - PDF(Abstract)

Back to course

Pdf Summary

This study examined whether a reduction in the dose of the targeted therapy drug, afatinib, could provide similar benefits to lung adenocarcinoma patients with EGFR sensitizing mutations. The researchers conducted a retrospective study using secondary data from 86 patients receiving afatinib as a first-line treatment at Persahabatan Hospital in Jakarta.<br /><br />Of the 86 patients, 43% received a dose reduction of afatinib due to adverse events. The most common adverse events leading to dose reduction were diarrhea, paronychia, skin rash, and stomatitis. The patients who received dose reduction were mainly female, 65 years old or older, had a deletion exon 19 mutation, and had a performance status of 0-1.<br /><br />The study found that patients who received dose reduction had a similar median progression-free survival (PFS) as those who received the full dose of afatinib. The median PFS for patients receiving 40mg/day, 30mg/day, and 20mg/day were 12 months, 15 months, and 14 months, respectively. However, there was no statistically significant difference between the different dose groups.<br /><br />The authors conclude that reducing the dose of afatinib can provide similar benefits to lung adenocarcinoma patients with EGFR sensitizing mutations. This suggests that dose reduction may be a viable option for managing adverse events associated with afatinib treatment.<br /><br />Overall, this study provides real-world evidence supporting the efficacy of dose reduction for afatinib in the treatment of EGFR-mutated lung adenocarcinoma.

Asset Subtitle

Widya Angasreni

Meta Tag

Speaker Widya Angasreni

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

reduction in dose

afatinib

lung adenocarcinoma

EGFR sensitizing mutations

retrospective study

adverse events

progression-free survival

PFS

real-world evidence

efficacy